Real-world data: come possono aiutare a migliorare la qualità dell’assistenza.

Competing Interests: Conflict of interest: GA, GA, GB, PC, EC, FD, CLV, MM, WM, AM, AP, WR, FRdM, FS and VT have nothing to declare. AA received personal fees and/or grants from BMS, MSD, Roche, Astra Zeneca, Eli-Lilly, Takeda e Bayer. GWC received personal fees and/or grants from A. Menarini, Alk-Abelló, Allergy Therapeutics, AstraZeneca-Medimmune, Boehringer Ingelheim, Chiesi Farmaceutici, Genentech, Guidotti-Malesci, Glaxo Smith Kline, Hal Allergy, Merck Sharp & Dome, Mundipharma, Novartis, Orion, Sanofi-Aventis, Sanofi Genzyme/Regeneron, Stallergenes-Greer, Uriach Pharma, Teva, Valeas, ViforPharma. GC received personal fees and/or grants from the European Community, AIFA, Ministeri dell’Università e Ricerca (MIUR), Novartis, GSK, Roche, AMGEN, BMS, Roche. APM received personal fees and/or grants from Bayer, Fresenius, Novartis. GM received personal fees and/or grants from Astra Zeneca, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, Menarini, Merck, Novartis, Recordati, Sandoz, Sanofi, Servier. AM received personal fees and/or grants from Ventana, Pierre Fabre, Verily, Abbvie, AstraZeneca, Verseau Therapeutics, Compungen, Myeloid Therapeutics, Third Rock Venture, Imcheck Therapeutics, Ellipses, Novartis, Roche, Macrophage Pharma, Bioveloclta, Merck, Principia, BMS, Johnson & Johnson. Declares commercial interest in Cedarlane Laboratories Ltd, HyCult Biotechnology, eBioscience, Biolegend, ABCAM PIc, Novus Biologicals, Enzo Life, Affymetrix. AR received personal fees and/or grants from Amgen, Pfizer, Sanofi, Novartis, Kite-Gilead, Celgene-BMS, Jazz, Omeros.